According to the Zhitong Finance App, Cansino Biotech (06185.HK) announced its 2026 interim results, with revenue of about 547 million yuan, up 46.1% year on year; gross profit of about 413 million yuan, up 39.4% year on year; net loss of 721,000 yuan, down 94.65% year on year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.